CCR5 and cancer: Given the critical role of CCL5 in cancer cell activity [23] and its high affinity for the receptor CCR5, we investigated whether targeting the CCL5–CCR5 axis could be an effective strategy in PDAC treatment using maraviroc, a selective CCR5 antagonist.